HFA 2025
Featured articles
HFA 2025 Highlights Podcast
CONTENTS
Online First
Gene Therapy and the Future of HF Management
Artificial intelligence in HF management
Consistent results for nexiguran ziclumeran across wildtype and variant ATTR-CM
New gene therapy for HFrEF passes phase 1 testing
MUSIC-HFpEF: Encouraging early results of novel gene therapy for HFpEF
Innovative Devices
FUTURE-HF: Novel IVC sensor may help control volume and improve function outcomes
C-MIC II: Cardiac microcurrent therapy in HFrEF
Updates on Finerenone
Real-world eligibility for finerenone: insights from the FIDELITY pooled analysis
FINEARTS-HF confirms: analysis suggests premature cessation of Finerenone is associated with risk and supports long-term treatment
FIVE-STAR: Mechanistic effects of finerenone in T2D plus CKD unravelled
New Therapies for Hypertrophic Cardiomyopathy
Novel HCM therapy shows potential
SEQUOIA-HCM: Aficamten effects consistent across regions
Large Trials, Big Impact
PRAISE-HFrEF: Is it safe to use GLP1-receptor agonists in clinically severe HF?
HELIOS-B: Health benefits of vutrisiran for ATTR-CM may increase over time
EMPEROR-Preserved: Diastolic dysfunction might predict response to empagliflozin
GALACTIC-HF: zooming in on efficacy data and subgroups
More Hot Trials from HFA
PREFER-HF: Is iron therapy helpful in HFpEF with iron deficiency?
SOGALDI-PEF: SGLT2 inhibitor plus MRA improves biomarker outcomes in HFp/mrEF
REDICAE: Diuretic withdrawal appears feasible in stable HFrEF
GLADIATOR: Anti-ulcer agent geranylgeranylacetone explored in HFpEF
